What is the official website of Novartis Norge ?

The official website of Novartis Norge is https://www.novartis.no/.

What is Novartis Norge's cybersecurity risk score?

Novartis Norge has an AI-generated cybersecurity risk score of 751 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Novartis Norge experienced?

According to Rankiteo, Novartis Norge currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Novartis Norge been affected by any supply chain cyber incidents ?

According to Rankiteo, Novartis Norge has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Novartis Norge have SOC 2 Type 1 certification ?

According to Rankiteo, Novartis Norge is not certified under SOC 2 Type 1.

Does Novartis Norge have SOC 2 Type 2 certification ?

According to Rankiteo, Novartis Norge does not hold a SOC 2 Type 2 certification.

Does Novartis Norge comply with GDPR ?

According to Rankiteo, Novartis Norge is not listed as GDPR compliant.

Does Novartis Norge have PCI DSS certification ?

According to Rankiteo, Novartis Norge does not currently maintain PCI DSS compliance.

Does Novartis Norge comply with HIPAA ?

According to Rankiteo, Novartis Norge is not compliant with HIPAA regulations.

Does Novartis Norge have ISO 27001 certification ?

According to Rankiteo,Novartis Norge is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Novartis Norge operate in ?

Novartis Norge operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Novartis Norge have ?

Novartis Norge employs approximately 46 people worldwide.

Does Novartis Norge own any subsidiaries ?

Novartis Norge presently has no subsidiaries across any sectors.

How many LinkedIn followers does Novartis Norge have ?

Novartis Norge's official LinkedIn profile has approximately 8,138 followers.

What is the NAICS classification code for Novartis Norge ?

Novartis Norge is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Novartis Norge have a Crunchbase profile ?

No, Novartis Norge does not have a profile on Crunchbase.

Does Novartis Norge have a LinkedIn profile ?

Yes, Novartis Norge maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/novartis-norge.

How many cybersecurity incidents has Novartis Norge experienced ?

As of October 2, 2026, Rankiteo reports that Novartis Norge has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Novartis Norge have ?

Novartis Norge has an estimated 5,771 peer or competitor companies worldwide.

What types of cybersecurity incidents has Novartis Norge faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Cyber Attack.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Novartis Norge

Boost Score +25 with badge (5 left)

751

/1000

Fair

776

/1000

Fair

Novartis Norge Vendor Cyber Rating & Cyber Score

novartis.no

Add Your Compliance Badge

Novartis er et nytenkende legemiddelselskap. Vi er først ute med nyskapende celle- og genterapier i Norge. Vi forsker og utvikler legemidler innen et bredt spekter av terapiområder, som kreft, kroniske- og sjeldne sykdommer. Vi er stolte av å være en konstruktiv samarbeidspartner som skaper nye løsninger i helsesektoren.

Novartis Norge

Novartis Norge CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Novartis

Breach

2/2026

NOV1774449180

Novartis Norge

Cyber Attack

100

06/2022

NOV21267722

Loading…

A.I.

Novartis Norge Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Novartis Norge

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Norge in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Novartis Norge in 2026.

Incident Types Novartis Norge vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Norge in 2026.

Incident History - Novartis Norge (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Novartis Norge Subsidiaries

Novartis Norge

Pharmaceutical Manufacturing

Website: https://www.novartis.no/

Company Size: 46

NovartisPharmaceutical Manufacturing

Novartis IndiaPharmaceutical Manufacturing

Novartis BrasilPharmaceutical Manufacturing

Novartis SciencePharmaceutical Manufacturing

Novartis Gene TherapiesBiotechnology Research

Novartis SlovakiaPharmaceutical Manufacturing

Novartis ItaliaPharmaceutical Manufacturing

Novartis USPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis MéxicoPharmaceutical Manufacturing

Novartis DeutschlandPharmaceutical Manufacturing

Novartis PortugalPharmaceutical Manufacturing

Novartis CanadaPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis Gulf | نوفارتس الخليجPharmaceutical Manufacturing

Novartis EspañaPharmaceutical Manufacturing

Novartis ColombiaPharmaceutical Manufacturing

Novartis US MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis ArgentinaPharmaceutical Manufacturing

Novartis, Australia & New ZealandPharmaceutical Manufacturing

Novartis SingaporePharmaceutical Manufacturing

Novartis NederlandPharmaceutical Manufacturing

Novartis Nederland - OncologieGeneesmiddelenproductie

Novartis Nederland - ReumatologieGeneesmiddelenproductie

Novartis Nederland - HematologieGeneesmiddelenproductie

Novartis Nederland - NeurologieGeneesmiddelenproductie

Novartis Nederland - Cardiovascular, Renal & Metabolism Geneesmiddelenproductie

Novartis Nederland - DermatologieGeneesmiddelenproductie

Novartis RomâniaPharmaceutical Manufacturing

Novartis SverigePharmaceutical Manufacturing

Novartis BeluxPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis DanmarkPharmaceutical Manufacturing

Novartis FinlandPharmaceutical Manufacturing

Novartis IsraelPharmaceutical Manufacturing

Novartis SerbiaPharmaceutical Manufacturing

Novartis Hong KongPharmaceutical Manufacturing

Novartis MagyarországPharmaceutical Manufacturing

Novartis MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis in SloveniaPharmaceutical Manufacturing

Novartis Ireland Pharmaceutical Manufacturing

Loading…

Novartis Norge Similar Companies

Zoetis

zoetis.com

The world’s leading animal health company. We’ve been innovating ways to predict, prevent, detect, and treat animal illness for over 70 years, and we continue to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers. Our leading portfolio and pipeline makes a difference in over 100 countries. Community Guidelines: This page is intended to share how Zoetis is advancing care for animals. We aspire to create a supportive community, but there are guidelines to which posts and comments on this page must adhere. If your post references a side effect related to any Zoetis product, we may contact you for more information. To monitor the safety of Zoetis products, we advise you to call our Veterinary Medical Information and Product Support Team at 1-888-963-8471; Support Team is available Mon-Fri 9am to 6:30pm ET. We reserve the right to remove any post/comment that violates LinkedIn Guidelines. As a last resort, we reserve the right to block users that demonstrate a repeated pattern of violating LinkedIn’s spirit of constructive, professional discourse. We respectfully request that you refrain from posting comments including: Unsolicited and/or unverified medical advice Vulgarity and/or profanity Discriminatory and/or derogatory comments, hate speech Politics and religion Personal attacks and/or threats Promotion of illegal activity Copyright/trademark infringements Topics that may be considered spam/advertising Our regular business hours are Mon-Fri 9am to 5pm ET. Zoetis does not endorse and is not responsible for information and opinions shared by community members. The information shared is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. Testimonials represent individual experience only and the experiences and opinions of community members may be unique to the speaker. Terms of Use: https://www.zoetis.com/terms-of-use

Teva Pharmaceuticals

tevapharm.com

Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/

Grifols

cb linktr.ee

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Viatris

viatris.com

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

Intas Pharmaceuticals

intaspharma.com

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.

Torrent Pharmaceuticals Ltd

cb torrentpharma.com

Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”

MANKIND PHARMA LTD

mankindpharma.com

Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries. Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products. Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients. Mankind strongly believes and follows its Core Values: 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External 𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone 𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities 𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals

Johnson & Johnson Innovative Medicine

jnj.com

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

Loading…

NEWS

Novartis Norge CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

January 30, 2025 08:00 AM

Novartis in Society Integrated Report 2024

Scope, reporting boundaries and data. This report covers all business and consolidated entities in line with the. Novartis Annual Report and...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-103761

SUMMARY

Mooncake transfer engine through 0.3.13.post1 contains a memory exhaustion vulnerability in TransferMetadata::receivePeerNotify that allows unauthenticated attackers to grow process memory without limit. Attackers can repeatedly send notify frames up to 1 MB to the handshake RPC port, filling the uncapped notifys vector until the out-of-memory killer terminates the engine.

Published

Date2026-10-01

Updated

Date2026-10-01

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

cvss4

Base Score: 8.7

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.6

Exploitability

3.9

REFERENCES

CVE-2026-103760

SUMMARY

Mooncake transfer engine through 0.3.13.post1 contains a denial of service vulnerability that allows unauthenticated remote attackers to block the handshake daemon by never reading replies. Attackers can send a Metadata request to the handshake RPC port and stall SocketHandShakePlugin's single listener thread in writeFully(), breaking all subsequent handshakes, metadata fetches, notify and probe requests.

Published

Date2026-10-01

Updated

Date2026-10-01

RISK INFORMATION (Score: 5.9)

cvss3

Base Score: 5.9

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:N/I:N/A:H

cvss4

Base Score: 8.2

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:P/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.6

Exploitability

2.2

REFERENCES

CVE-2025-71427

SUMMARY

Office-PowerPoint-MCP-Server through 2.0.7 contains a path traversal vulnerability that allows MCP callers to write and read files outside the working directory by supplying absolute paths or ../ sequences. Attackers can steer an AI agent via prompt injection to abuse save_presentation, open_presentation, or manage_image output_path to overwrite any server-writable file or load external files.

Published

Date2026-10-01

Updated

Date2026-10-01

RISK INFORMATION (Score: 6.8)

cvss3

Base Score: 6.8

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:R/S:U/C:H/I:H/A:N

cvss4

Base Score: 7.6

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:P/PR:N/UI:P/VC:H/VI:H/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.2

Exploitability

1.6

REFERENCES

CVE-2026-86344

SUMMARY

A flaw was found in 389-ds-base. An unauthenticated remote attacker can send a complete LDAP operation followed by the first bytes of an incomplete LDAPMessage on the same connection, causing the server to hand that connection to a second worker thread before the first worker's result is flushed. The second worker blocks until nsslapd-ioblocktimeout while holding the connection mutex, preventing delivery of the completed operation's result. Repeating this across a small number of connections proportional to the configured worker-thread pool size exhausts the entire pool under default configuration, denying service to all clients (anonymous and authenticated, plaintext and TLS) for as long as the attacker maintains the connections.

Published

Date2026-10-01

Updated

Date2026-10-01

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

3.9

REFERENCES

CVE-2026-71454

SUMMARY

Improper neutralization of input during web page generation ('cross-site scripting') vulnerability in CWE-79 - Cross-site Scripting CAPEC-63 allows Cross-Site Scripting (XSS). This issue affects CAPEC-63: before 3.0b63.

Published

Date2026-10-01

Updated

Date2026-10-01

RISK INFORMATION (Score: )

cvss4

Base Score: 5.8

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:H/SI:H/SA:H/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

https://www.johnsoncontrols.com/trust-center/cybersecurity/security-advisories

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

Novartis Norge Vendor Cyber Rating & Cyber Score

Novartis Norge A.I CyberSecurity Scoring

Novartis Norge CyberSecurity News & History

Novartis Norge Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Novartis Norge

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Novartis Norge vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Novartis Norge (X = Date, Y = Severity)

Novartis Norge Subsidiaries

Novartis Norge

Novartis Norge Similar Companies

Zoetis

Teva Pharmaceuticals

Grifols

AbbVie

Viatris

Intas Pharmaceuticals

Torrent Pharmaceuticals Ltd

MANKIND PHARMA LTD

Johnson & Johnson Innovative Medicine

Novartis Norge CyberSecurity News

Novartis in Society Integrated Report 2024

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo

Novartis Norge CyberSecurity News & History

Novartis Norge Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Novartis Norge

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Novartis Norge vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Novartis Norge (X = Date, Y = Severity)

Novartis Norge Subsidiaries

Novartis Norge

Novartis Norge Similar Companies

Zoetis

Teva Pharmaceuticals

Grifols

AbbVie

Viatris

Intas Pharmaceuticals

Torrent Pharmaceuticals Ltd

MANKIND PHARMA LTD

Johnson & Johnson Innovative Medicine

Novartis Norge CyberSecurity News

Novartis in Society Integrated Report 2024

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo